Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design

被引：31

作者：

Bradley, Deborah A. ^{[1
]}

Dunn, Rodney ^{[1
]}

Nanus, David ^{[2
]}

Stadler, Walter ^{[3
]}

Dreicer, Robert ^{[4
]}

Rosenberg, Jonathan ^{[5
]}

Smith, David C. ^{[1
]}

Hussain, Maha ^{[1
]}

机构：

[1] Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA

[2] Cornell Univ, Weill Med Coll, New York, NY USA

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Cleveland Clin Fdn, Cleveland, OH 44195 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

CLINICAL GENITOURINARY CANCER | 2007年 / 5卷 / 07期

关键词：

angiogenesis; bladder cancer; transitional cell carcinoma;

D O I：

10.3816/CGC.2007.n.037

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic chemotherapy is the primary treatment modality for patients with advanced urothelial cancer. However, despite a high initial response rate, durable responses are rare. Angiogenesis has been shown to be important in the development and progression of urothelial cancer. Sunitinib, an oral, multi-targeted, small-molecule inhibitor of multiple tyrosine kinases, is known to inhibit angiogenesis and therefore might decrease progression of urothelial cancer. This phase II trial was designed to investigate the role of sunitinib as maintenance therapy in patients with advanced urothelial cancer. The specific hypothesis of this trial is that sunitinib will decrease progression rates in patients with advanced urothelial cancer who have obtained stable disease or better after standard chemotherapy.

引用

页码：460 / 463

页数：4

共 31 条

[1] Novel approaches with targeted therapies in bladder cancer - Therapy of bladder cancer by blockade of the epidermal growth factor receptor family [J].